Drug Trial Radar · NCT07667322
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Dec 17, 2024
Primary completion
Sep 1, 2026
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single ascending doses of ocrelizumab SC during an initial dose-escalation phase, with the option to continue treatment with the selected dose of ocrelizumab SC in the dose-continuation phase.
Conditions
- Multiple Sclerosis
Interventions
Ocrelizumab Co-formulated With rHuPH20Drug
Participants will receive ocrelizumab co-formulated with rHuPH20, as a SC injection, per the schedule specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Up to 168 weeks
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Profound Research, LLC
Carlsbad, California
Neurology Associates, PA
Maitland, Florida
University of South Florida
Tampa, Florida
Shepherd Center Inc.
Atlanta, Georgia
John Hopkins University School of Medicine
Baltimore, Maryland
Hope Neurology
Knoxville, Tennessee
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
Centro de Pesquisas Clinicas
São Paulo, São Paulo, Brazil
Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C.
Guadalajara, Jalisco, Mexico
Inovacion y Desarrollo en ciencias de la salud
Mexico City, Mexico CITY (federal District), Mexico
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Morriston Hospital
Swansea, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.